Parent and patient perceptions of medical marijuana in the childhood cancer context.
Prasanna J AnanthAnna RevetteAnne Reed-WestonPorag DasJoanne WolfePublished in: Pediatric blood & cancer (2020)
Patients and families are receptive to using MM, motivated by potential for symptom relief and cancer-directed effects. Yet, lack of empiric evidence is a barrier, underscoring the need for robust clinical trial data to support MM recommendations and use.
Keyphrases
- childhood cancer
- clinical trial
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- young adults
- primary care
- prognostic factors
- electronic health record
- squamous cell carcinoma
- randomized controlled trial
- study protocol
- clinical practice
- open label
- artificial intelligence
- deep learning
- double blind
- phase iii